Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡

by Xue, Fei, Ma, Haijun, Stehman-Breen, Catherine, Haller, Christine, Katz, Leonid, Wagman, Rachel B, Critchlow, Cathy W, Denosumab Global Safety Assessment Team
Published 2013